A new area of cancer immunotherapy is enhancing therapeutic mAb-mediated CD16 activation of NK cells. CAR-NK cells containing multi-specific molecules made up of relatively stable CD16 and other ...

NK cells recognize cell-bound antibodies via CD16A (FcγRIIIA) to mediate antibody-dependent cellular cytotoxicity (ADCC). Potentiating therapeutic mAb-mediated CD16 activation of NK cells is an ...

Although NK cells have natural antibody-binding molecules such as CD16, their ability to hold onto antibodies long-term is ...

The bispecifics are differentiated through their targeting of NKp46 to engage NK cells, rather than the CD16 and NKG2D receptors targeted by other bispecifics. Importantly, NKp46 expression is ...

Yago Nieto, MD, PhD, discusses AFM13, how it works, and its effect as a bispecific antibody that targets CD30 and CD16.

SAR443579 (also known as IPH6101) is a tri-functional NKp46/CD16-based anti-CD123 NK cell engager – described as a first-in-class therapy – that has now advanced into a phase 2 programme.